Geode Capital Management, LLC Inhibrx, Inc. Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$32.76 - $39.56 $572,153 - $690,915	17,465 Added 2.54%	704,825 $24.6 Million
Q4 2023 Feb 13, 2024	BUY	$14.5 - $38.0 $597,414 - $1.57 Million	41,201 Added 6.38%	687,360 $26.1 Million
Q3 2023 Nov 13, 2023	SELL	$15.75 - $26.31 $202,608 - $338,451	-12,864 Reduced 1.95%	646,159 $11.9 Million
Q2 2023 Aug 11, 2023	BUY	$16.96 - $27.82 $834,533 - $1.37 Million	49,206 Added 8.07%	659,023 $17.1 Million
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $629,514 - $926,016	34,120 Added 5.93%	609,817 $11.5 Million
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $1.59 Million - $2.63 Million	78,890 Added 15.88%	575,697 $14.2 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $737,507 - $1.58 Million	63,688 Added 14.7%	496,807 $8.92 Million
Q2 2022 Aug 12, 2022	SELL	$8.52 - $25.26 $147,574 - $437,528	-17,321 Reduced 3.85%	433,119 $4.92 Million
Q1 2022 May 13, 2022	BUY	$19.89 - $43.18 $408,898 - $887,694	20,558 Added 4.78%	450,440 $10 Million
Q4 2021 Feb 11, 2022	SELL	$26.75 - $46.02 $437,121 - $752,012	-16,341 Reduced 3.66%	429,882 $18.8 Million
Q3 2021 Nov 12, 2021	BUY	$25.18 - $37.81 $3.18 Million - $4.78 Million	126,382 Added 39.51%	446,223 $14.9 Million
Q2 2021 Aug 13, 2021	BUY	$14.69 - $27.52 $2.49 Million - $4.66 Million	169,371 Added 112.56%	319,841 $8.8 Million
Q1 2021 May 12, 2021	BUY	$16.27 - $41.26 $14,968 - $37,959	920 Added 0.62%	150,470 $3.02 Million
Q4 2020 Feb 12, 2021	BUY	$15.96 - $50.0 $2.07 Million - $6.47 Million	129,465 Added 644.59%	149,550 $4.93 Million
Q3 2020 Nov 13, 2020	BUY	$16.77 - $20.65 $336,825 - $414,755	20,085 New	20,085 $361,000

Others Institutions Holding INBX

# of Institutions

Shares Held

25.3K

Call Options Held

Put Options Held

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account